Skip to Content

Treprostinil Pregnancy and Breastfeeding Warnings

Treprostinil is also known as: Orenitram, Remodulin, Tyvaso

Treprostinil Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed. AU TGA pregnancy category: B3 US FDA pregnancy category: C (tablets) US FDA pregnancy category: B (oral inhalation, parenteral)

Animal studies in pregnant rats have failed to reveal evidence of teratogenicity at higher doses when administered by continuous subcutaneous infusion during organogenesis and late gestational development. Animal studies in pregnant rabbits have revealed evidence of increased fetal skeletal variations (bilateral full rib or rudimentary right rib on lumbar 1) at doses that produced maternal toxicity. Animal studies with the extended-release tablets revealed dose-dependent decreases in body weight gain and food consumption as well as increased post-implantation loss, decreased pregnancy rates, and fetal skeletal malformations at higher doses. Animal reproduction studies with the inhalation formulation have not been conducted. There are no controlled data in human pregnancy. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Treprostinil Breastfeeding Warnings

Use with caution; according to some authorities, use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Unknown Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Tyvaso (treprostinil)." United Therapeutics Corporation, Silver Spring, MD.
  2. "Product Information. Orenitram (treprostinil)." United Therapeutics Corporation, Silver Spring, MD.
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.

References for breastfeeding information

  1. "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.
  2. "Product Information. Tyvaso (treprostinil)." United Therapeutics Corporation, Silver Spring, MD.
  3. "Product Information. Orenitram (treprostinil)." United Therapeutics Corporation, Silver Spring, MD.
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  5. Cerner Multum, Inc. "Australian Product Information." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide